Every letter below is real, public, and pulled directly from FDA's own warning letter database. No speculation, no "industry sources say." Just what the FDA found, and what it means if a supplier on this list, or one that looks like them, is in your supply chain.
The 10 letters
1. Smart Surgical, Inc., dba Burst Biologics (Feb 2022) Sold umbilical cord blood products (BioBurst Fluid, BioBurst Rejuv) that failed to meet the criteria for minimal manipulation under 21 CFR 1271.15, pulling them out of the lighter-touch tissue category and into full drug/biologic territory.
For a doctor: if your supplier's product doesn't actually qualify for the regulatory category it's marketed under, you're the one holding the liability when a patient or board asks.
2. Kimera Labs, Inc. (Sep 2023) Exosome products marketed as unapproved new drugs and unlicensed biologics.
For a doctor: one of the earliest, most-cited exosome warning letters. If a supplier still references Kimera favorably or doesn't know this history, that's a knowledge gap you don't want in a partner.
3. Platinum Biologics LLC (Aug 2025)
Two umbilical cord products (Nano PRP Jelly, Nano Flex) and two exosome products (NanoEx, Nano Xsomes) sold for allogeneic use, all cited as unapproved new drugs and unlicensed biologics.
For a doctor: four different products, two categories, one letter. When half a supplier's catalog is exosome-branded and the other half isn't, both halves can still fail the same test, disease and structure/function claims don't care what the product is called.
4. Mother Stem Institute, Corp. (Aug 2024) Adipose-derived stromal vascular fraction (SVF), administered IV, marketed for a broad range of diseases and conditions with no approval behind it.
For a doctor: broad disease claims with no clinical backing are the single fastest way for a product to attract FDA attention, and the fastest way for you to attract a medical board complaint.
5. Evolutionary Biologics Inc. (Dec 2024) Three products, including an exosome line (EXO RNA), cited as unapproved new drugs and unlicensed biologics, marketed with specific structure/function and disease-related claims.
For a doctor: the letter explicitly ties the violation to marketing language, not just the product itself. Read what your supplier's marketing actually says, not just what's on the CoA.
6. Chara Biologics, Inc. (Jan 2025) Cited for an exosome product (CharaExo) and two umbilical cord products, after the FDA had first raised concerns with the same company back in 2019.
For a doctor: five years between first contact and a formal warning letter. A supplier can look established and still be sitting on an unresolved compliance issue the whole time.
7. Supreme Rejuvenation, LLC (May 2025) Umbilical cord MSC-derived exosomes sold with zero IND application and zero biologics license in effect, despite disclaimers on the site calling the products "investigational."
For a doctor: a disclaimer saying "research use only" doesn't change what the FDA considers the product to actually be. If it's being sold and used clinically, the label doesn't override the law.
8. New Life Medical Services, LLC (Sep 2025) Five products, including an exosome product called Rexo, all cited as unapproved new drugs and unlicensed biologics.
For a doctor: a full product line caught at once. When one product in a supplier's catalog gets flagged, it's worth asking whether the rest of the line has the same underlying problem.
9. Dynamic Stem Cell Therapy (Feb 2026) Umbilical cord-derived stem cell product cited for misbranding while held for sale in interstate commerce.
For a doctor: misbranding is a labeling and claims issue, separate from whether the product itself is dangerous. It still creates real legal exposure for whoever administers it.
10. R3 Medical Companies (Aug 2026) The most detailed recent letter. Multiple co-located entities selling Wharton's jelly and cord blood products, two labeled as exosome preparations. FDA found the products failed the "homologous use" test, and separately noted that the manufacturing process described for the "exosome" products didn't appear to actually isolate exosomes.
For a doctor: the label said exosomes. The process apparently didn't produce exosomes. This is the exact scenario a Certificate of Analysis and third-party particle testing exist to catch, and the exact scenario where "trust the label" isn't good enough.
The pattern, in plain English
Ten companies, four years, one repeating story:
- Marketed as a drug, sold like a supplement. Disease claims trigger drug/biologic status regardless of what category the seller says it's in.
- Labels that outrun the manufacturing. More than once, what's on the vial isn't fully backed by what the process actually produced.
- "Research use only" doesn't save you. Several letters explicitly reject disclaimers as a shield when the product is clearly being marketed and used clinically.
- The FDA doesn't forget. Multiple companies had prior contact from the agency, years earlier, before the formal letter landed.
What to demand before you place an order
Every issue above gets caught by paperwork, not promises. Ask for:
- FDA tissue establishment registration number, not just the phrase "FDA registered."
- Current AATB, AABB, or NMDP accreditation certificate.
- Lot-specific Certificate of Analysis for the exact product you're ordering.
- Third-party nanoparticle tracking analysis (NTA) confirming particle count and type, especially for anything labeled "exosomes."
- Donor eligibility screening records.
- A direct answer on whether the product falls under cGTP (21 CFR Part 1271), cGMP, or both, and why.
If any answer is vague, that's the answer.
Where BioRegen fits
BioRegen, a Florida-based distributor of 3D-cultured stem cells and exosomes, states that its facility is FDA-registered and inspected, AATB-accredited, and compliant with cGMP and cGTP standards, with every batch shipping a Certificate of Analysis and third-party NTA testing, and that its manufacturing complies with Florida's SB 1768.
If you are ready to source premium biologics, get in touch with BioRegen today.
FAQ
Does a warning letter mean the product is unsafe? Not necessarily. It means the marketing or manufacturing didn't meet federal legal requirements. It's a compliance finding, not a clinical verdict, though several letters do cite quality and sterility gaps that are directly safety-relevant.
How do I check a supplier myself? FDA's warning letter database is public and searchable at fda.gov. Two minutes, no account needed.
Is "exosomes" on a label always accurate? No, based on letter #10 above. Ask for the NTA data that proves the particles in the vial are actually exosomes.
References
- FDA Warning Letters (all available at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters): Smart Surgical Inc dba Burst Biologics (Feb 2022), Kimera Labs (Sep 2023), Signature Biologics LLC (Sep 2023, closed Feb 2025), Mother Stem Institute (Aug 2024), Evolutionary Biologics (Dec 2024), Chara Biologics (Jan 2025), Supreme Rejuvenation (May 2025), New Life Medical Services (Sep 2025), Dynamic Stem Cell Therapy (Feb 2026), R3 Medical Companies (Aug 2026).
- "Public Safety Notification on Exosome Products," U.S. FDA, Dec. 2019. Available: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products
- "Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of HCT/Ps," U.S. FDA. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and
Educational content, not legal or medical advice. There are currently no FDA-approved exosome products for any therapeutic use in the United States. Verify any supplier's documentation directly.
